SLC5A2 and plasma cell myeloma: Further, in individuals diagnosed with both type 2 diabetes mellitus and either acute myeloid leukemia, chronic myeloid leukemia, or multiple myeloma, SGLT2 inhibitor use was associated with an increased risk of mortality.